Jincheng Pharm(SZ:300233) Xin Lang Cai Jing·2026-02-02 01:28Core Viewpoint - Jincheng Pharmaceutical experienced a decline of 2.29% on January 30, with a trading volume of 114 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On January 30, Jincheng Pharmaceutical had a financing buy-in amount of 13.56 million yuan and a financing repayment of 13.38 million yuan, resulting in a net financing buy of 189,100 yuan [1]. - The total financing and securities balance for Jincheng Pharmaceutical reached 417 million yuan, with the financing balance accounting for 7.05% of the circulating market value, which is above the 50th percentile level over the past year [1]. - In terms of securities lending, there were no shares repaid on January 30, with 300 shares sold short, amounting to 4,611 yuan at the closing price [1]. Company Performance - As of January 20, the number of shareholders for Jincheng Pharmaceutical increased by 4.95% to 29,100, while the average circulating shares per person decreased by 4.72% to 12,768 shares [2]. - For the period from January to September 2025, Jincheng Pharmaceutical reported a revenue of 1.932 billion yuan, a year-on-year decrease of 23.19%, and a net profit attributable to shareholders of 31.58 million yuan, down 79.10% year-on-year [2]. Dividend and Shareholding Information - Since its A-share listing, Jincheng Pharmaceutical has distributed a total of 933 million yuan in dividends, with 323 million yuan distributed over the past three years [3]. - As of September 30, 2025, among the top ten circulating shareholders, the "Fuguo Precision Medical Flexible Allocation Mixed A" fund is the fourth largest shareholder with 4.961 million shares, while "Hong Kong Central Clearing Limited" is the eighth largest with 3.336 million shares, having decreased by 2.135 million shares from the previous period [3].